全文获取类型
收费全文 | 2356876篇 |
免费 | 198027篇 |
国内免费 | 4175篇 |
专业分类
耳鼻咽喉 | 34235篇 |
儿科学 | 72518篇 |
妇产科学 | 62917篇 |
基础医学 | 332046篇 |
口腔科学 | 67458篇 |
临床医学 | 214286篇 |
内科学 | 464181篇 |
皮肤病学 | 47891篇 |
神经病学 | 199243篇 |
特种医学 | 95844篇 |
外国民族医学 | 886篇 |
外科学 | 359316篇 |
综合类 | 56147篇 |
现状与发展 | 1篇 |
一般理论 | 977篇 |
预防医学 | 189119篇 |
眼科学 | 55325篇 |
药学 | 177009篇 |
4篇 | |
中国医学 | 4258篇 |
肿瘤学 | 125417篇 |
出版年
2018年 | 24201篇 |
2016年 | 20571篇 |
2015年 | 23278篇 |
2014年 | 33532篇 |
2013年 | 50825篇 |
2012年 | 68732篇 |
2011年 | 72269篇 |
2010年 | 42467篇 |
2009年 | 40860篇 |
2008年 | 68754篇 |
2007年 | 73092篇 |
2006年 | 73993篇 |
2005年 | 72032篇 |
2004年 | 69298篇 |
2003年 | 66863篇 |
2002年 | 66095篇 |
2001年 | 112284篇 |
2000年 | 116225篇 |
1999年 | 97684篇 |
1998年 | 26155篇 |
1997年 | 23778篇 |
1996年 | 23734篇 |
1995年 | 24451篇 |
1994年 | 23021篇 |
1993年 | 21429篇 |
1992年 | 79261篇 |
1991年 | 76373篇 |
1990年 | 73532篇 |
1989年 | 70790篇 |
1988年 | 65776篇 |
1987年 | 64749篇 |
1986年 | 61288篇 |
1985年 | 58365篇 |
1984年 | 44145篇 |
1983年 | 37541篇 |
1982年 | 22794篇 |
1981年 | 20226篇 |
1980年 | 18931篇 |
1979年 | 41221篇 |
1978年 | 28910篇 |
1977年 | 24246篇 |
1976年 | 22753篇 |
1975年 | 23902篇 |
1974年 | 29585篇 |
1973年 | 28008篇 |
1972年 | 26204篇 |
1971年 | 24141篇 |
1970年 | 22724篇 |
1969年 | 21062篇 |
1968年 | 19113篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
91.
Michael T Milano Veronica L S Chiang Scott G Soltys Tony J C Wang Simon S Lo Alexandria Brackett Seema Nagpal Samuel Chao Amit K Garg Siavash Jabbari Lia M Halasz Melanie Hayden Gephart Jonathan P S Knisely Arjun Sahgal Eric L Chang 《Neuro-oncology》2020,22(12):1728
BackgroundThe American Radium Society (ARS) Appropriate Use Criteria brain malignancies panel systematically reviewed (PRISMA [Preferred Reporting Items for Systematic Reviews and Meta-Analyses]) published literature on neurocognitive outcomes after stereotactic radiosurgery (SRS) for patients with multiple brain metastases (BM) to generate consensus guidelines.MethodsThe panel developed 4 key questions (KQs) to guide systematic review. From 11 614 original articles, 12 were selected. The panel developed model cases addressing KQs and potentially controversial scenarios not addressed in the systematic review (which might inform future ARS projects). Based upon quality of evidence, the panel confidentially voted on treatment options using a 9-point scale of appropriateness.ResultsThe panel agreed that SRS alone is usually appropriate for those with good performance status and 2–10 asymptomatic BM, and usually not appropriate for >20 BM. For 11–15 and 16–20 BM there was (between 2 case variants) agreement that SRS alone may be appropriate or disagreement on the appropriateness of SRS alone. There was no scenario (among 6 case variants) in which conventional whole-brain radiotherapy (WBRT) was considered usually appropriate by most panelists. There were several areas of disagreement, including: hippocampal sparing WBRT for 2–4 asymptomatic BM; WBRT for resected BM amenable to SRS; fractionated versus single-fraction SRS for resected BM, larger targets, and/or brainstem metastases; optimal treatment (WBRT, hippocampal sparing WBRT, SRS alone to all or select lesions) for patients with progressive extracranial disease, poor performance status, and no systemic options.ConclusionsFor patients with 2–10 BM, SRS alone is an appropriate treatment option for well-selected patients with good performance status. Future study is needed for those scenarios in which there was disagreement among panelists. 相似文献
92.
Hallet Julie Look Hong Nicole J. Zuk Victoria Davis Laura E. Gupta Vaibhav Earle Craig C. Mittmann Nicole Coburn Natalie G. 《Gastric cancer》2020,23(3):373-381
Gastric Cancer - Esophagogastric cancer (EGC) is one of the deadliest and costliest malignancies to treat. Care by high-volume providers can provide better outcomes for patients with EGC. Cost... 相似文献
93.
Kerryn W. Reding Aaron K. Aragaki Richard K. Cheng Ana Barac Sylvia Wassertheil-Smoller Jessica Chubak Marian C. Limacher W. Gregory Hundley Ralph D'Agostino Jr. Mara Z. Vitolins Theodore M. Brasky Laurel A. Habel Eric J. Chow Rebecca D. Jackson Chu Chen April Morgenroth Wendy E. Barrington Matthew Banegas Matthew Barnhart Rowan T. Chlebowski 《The oncologist》2020,25(8):712-721
94.
95.
96.
Michael Staehler Peter J. Goebell Lothar Müller Till-Oliver Emde Natalie Wetzel Lisa Kruggel Martina Jänicke Norbert Marschner the RCC-Registry Group 《International journal of cancer. Journal international du cancer》2020,146(5):1307-1315
Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC. 相似文献
97.
98.
99.
Clinical and Translational Oncology - Breast cancer with positive hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) is a special subgroup with different clinical features... 相似文献
100.